🧪 These lines aim to standardize manufacturing, reduce costs, and improve patient access to treatments.
💼 The lines include a transient cell line for speed and flexibility, a packaging cell line for screening genes, and a producer cell line for stable integration of required genes.
💡 Stable cell lines can streamline production and reduce costs for viral vector-based gene therapies.
🔬 Cytiva is also addressing the quality challenge of encapsidated host cell DNA impurities during production.
🚀 The company aims to provide end-to-end solutions for viral vector manufacturing, improving patient access.
Introduction:
Cytiva has introduced new cell manufacturing lines for viral vectors in order to address the challenges and limitations associated with inefficient manufacturing methods and the lack of standardized processes in the field of viral vector-based gene therapies. These new cell lines aim to streamline the manufacturing process, reduce costs, and improve patient access to these therapies.
- Cytiva has created three cell lines for adeno-associated virus (AAV) production that meet the objectives of various therapeutic programs. These cell lines can be easily integrated into existing workflows and can be paired with Cytiva’s cell culture media.
- The first cell line is a transient line that provides speed and flexibility, the second is a packaging line that eases the screening of genes of interest, and the third is a producer line that stably integrates all four required genes for AAV production.
- Using stable cell lines can simplify workflows, reduce raw materials, and lead to reduced costs and faster market access for viral vector-based gene therapies.
- Cytiva is also working on a genetic modification to reduce encapsidated host cell DNA (hcDNA), which is a quality challenge in viral vector production.
- The new cell lines and the reduction of hcDNA offer end-to-end solutions for viral vector manufacturing, allowing for higher quality treatments and improved patient access.
Conclusion:
Cytiva’s new cell manufacturing lines for viral vectors have the potential to revolutionize the field of gene therapies by standardizing the manufacturing process and reducing costs. With the ability to integrate these cell lines into existing workflows and the reduction of quality challenges such as hcDNA, these advancements can significantly improve patient access to viral vector-based gene therapies.
